Background. Gastrointestinal system disorders are known to be prevalent among children with autism spectrum disorder (ASD). Some ASD-associated comorbidities are abdominal pain, constipation, diarrhea, gastroesophageal reflux, sleep disturbances, epilepsy, and psychiatric problems. Nonetheless, there is still limited information about the presence of functional GI disorders (FGIDs) among children with ASD, especially in Türkiye. Using the Rome criteria, we aimed to investigate FGIDs in children with ASD. Methods. The sample of the study consisted of 68 children aged 4-10 years, diagnosed with ASD according to the DSM-5 diagnostic criteria and had scores greater than 30 on the Childhood Autism Rating Scale (CARS-2) and an age-sex matched control group (n=78). The Rome III criteria were used to evaluate FGIDs. Results. The frequency of FGIDs in the ASD group was higher (76.5%) compared to the control group (p<0.001). Compared to the control group, abdominal migraine frequency increased 10 times (p=0.012), functional constipation 7 times (p<0.001), and fecal incontinence 6 times (p<0.001) in the ASD group. Stool retention was not present in most children in the ASD group who were found to have fecal incontinence. Conclusion. In this study, the most common FGIDs in the ASD group were abdominal migraine, functional constipation, and non-retentive fecal incontinence. The finding that most children with ASD who had fecal incontinence did not show stool retention implicated social, psychological, and behavioral factors as the causes of incontinence. Raising awareness of healthcare professionals about the frequency of FGIDs in children with ASD will improve many areas in the daily lives of these children.
Background: This study aimed to evaluate the indications, efficacy, and safety of endoscopic retrograde cholangiopancreatography (ERCP) in pediatric patients at a single center in Turkey between 2017 and 2021. Methods: A retrospective review was conducted on 50 children (mean age, 12.7 years; range, 1–18 years) who underwent 65 ERCP procedures. Data collected included patient demographics, indications for ERCP, procedural details, success rates, and complications. All procedures were performed using therapeutic duodenoscopes under conscious sedation administered by an anesthesiologist. Results: The primary indications for ERCP were biliary tract issues, including choledocholithiasis (52.3%) and chronic pancreatitis (18.5%). The overall cannulation success rate was 92.3%. Multiple therapeutic interventions, such as sphincterotomies and stent placements, were often required. The most common complication was post-ERCP pancreatitis, observed in 6.1% of cases, all of which were moderate. No fatalities or serious anesthesia-related adverse events were reported. Conclusion: ERCP is an effective and safe therapeutic procedure in pediatric patients when performed in collaboration with adult gastroenterologists, despite technical challenges such as the lack of pediatric-specific duodenoscopes. The findings highlight the need for specialized pediatric ERCP equipment and suggest that centralized ERCP facilities could enhance patient outcomes in Turkey.
Pediatric eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder defined by esophageal dysfunction and eosinophilic infiltration of the esophageal mucosa. Its incidence is increasing, particularly among children. However, assessing disease severity and monitoring treatment response over time remain challenging. Conventional histological methods often fail to capture ongoing inflammation or predict symptom recurrence. This study aimed to evaluate the utility of a multimodal approach incorporating clinical symptom scoring (Pediatric Eosinophilic Esophagitis Symptom Score [PEESS]), endoscopic findings (Eosinophilic Esophagitis Reference Score [EREFS]), and subepithelial imaging (endoscopic ultrasonography [EUS]) for the diagnosis, treatment monitoring, and long-term follow-up of pediatric EoE. We conducted a retrospective review of 23 pediatric patients diagnosed with EoE between 2018 and 2022 at a tertiary care center. Diagnosis was based on clinical presentation, endoscopic appearance, and histological confirmation (≥15 eosinophils/high-power field). All patients received a combination of proton pump inhibitors, topical corticosteroids, and personalized elimination diets. PEESS and EREFS scores were assessed before and after treatment. EUS was performed in a subset of patients to evaluate esophageal wall changes. The median age at diagnosis was 11 years. Atopic comorbidities were identified in 82.6% of patients. Post-treatment, both PEESS and EREFS scores showed significant improvements. Histological remission was achieved in 95.6% of cases. Among the 8 patients who underwent EUS, persistent esophageal wall thickening was observed despite mucosal healing, suggesting ongoing subepithelial inflammation. Long-term dietary management without steroids was successful in a subset of patients after initial remission. PEESS and EREFS are valuable, complementary tools for assessing treatment response in pediatric EoE. EUS provides additional insights into residual disease activity beyond mucosal healing. This multimodal evaluation may facilitate personalized, less-invasive, and more effective long-term management of pediatric EoE.
Background/Objectives: Early cow’s milk formula (CMF) exposure in the neonatal period has been proposed as a risk factor for cow’s milk protein allergy (CMPA), although evidence remains inconsistent. This study evaluated the association between CMF use within the first 72 h and later CMPA. Methods: This retrospective study included 106 CMPA infants and 106 controls. CMPA was diagnosed according to ESPGHAN 2024 guidelines using clinical assessment, a 2–4-week elimination diet, and a supervised oral food challenge. Demographic and feeding data were collected, and logistic regression identified independent predictors. Results: Early CMF exposure was more common in the CMPA group (76% vs. 59%; p = 0.006). Multivariate analysis confirmed early CMF exposure as an independent risk factor (aOR: 2.35; 95% CI: 1.18–4.68). A subgroup with CMF intake limited to the first 72 h followed by exclusive breastfeeding was markedly overrepresented among CMPA cases (47% vs. 12%; p < 0.001). Early CMF exposure did not significantly impact IgE versus non-IgE phenotype distribution. Family history of atopy also remained a strong predictor. Conclusions: Early CMF exposure during the first 72 h and family history of atopy were key risk factors for CMPA. Supporting breastfeeding initiation and avoiding unnecessary early CMF supplementation may help reduce CMPA incidence.